Skip to main content
Caplight Logo









VDyne

VDyne

Private
Maple Grove, MinnesotaHealthcare & Life Scienceshttps://www.vdyne.com/

Last Round

VC Round

Oct 24, 2022

Total Funding Raised

$21M

Momentum

Top 1%

of companies Caplight tracks

Company Overview

VDyne is a medical device company developing a minimally invasive transcatheter valve replacement system to treat tricuspid regurgitation.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

transcatheter tricuspid valve replacementTTVRtricuspid regurgitationstructural heart deviceheart valve replacementminimally invasive valve replacementinterventional cardiologycardiac devicecatheter-based deliveryFDA Breakthrough Devicerepositionable valveretrievable valveclinical-stage medical device

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

VDyne Comparables

Compare VDyne with similar companies based on industry and business-model similarity.

VDyne comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Laplace Interventional
93%
T-Heart
93%
Trisol Medical
92%

VDyne Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundOct 24, 2022
Series CJan 6, 2021

Key People

Founding team and executive leadership

Mike Buck

Chairman And CEO

Executive Team

VDyne Investors

Notable investors and investment history

VDyne investors
InvestorRounds
Jean Boulle MedtechVC Round, Series C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 26, 2026

    Grew 28% QoQ from 39 to 50 employees.

  • Aug 22, 2026

    Monthly visitors increased 33% MoM.

Recent news

Latest coverage and updates

  • is_developingJul 29, 2026

    VDyne, Inc. is developing transcatheter tricuspid valve replacement system.

  • is_developingJul 29, 2026

    VDyne, Inc. was planning to develop transcatheter tricuspid valve replacement system for the treatment of tricuspid regurgitation on Jul 29th '26.

VDyne Filings

Explore SEC and related filing metadata, where available.

VDyne filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about VDyne's valuation, stock price, and market status.

Is VDyne a public or private company?

VDyne is a private company.

What is the current stock price of VDyne?

VDyne is a private company with no public stock price. No recent secondary market data is available.

How much is VDyne worth (valuation)?

Valuation information for VDyne is not publicly available.

Can I buy VDyne stock?

VDyne shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was VDyne's last funding round?

VDyne's most recent funding round was VC Round on October 24, 2022.

Who are the main investors in VDyne?

Key investors in VDyne include Jean Boulle Medtech.

Will VDyne IPO soon?

No public IPO plans have been announced for VDyne.

How can I track VDyne secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor VDyne's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersMaple Grove, Minnesota
Employee Range50
Year Founded2017
Last FundingOct 24, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?